| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-08-11 | Mydicar® | heart failure |
Celladon (USA - CA) Imperial College London (UK) British Heart Foundation (UK) | Cardiovascular diseases | |
| 2014-08-11 | Bosulif® (bosutinib) | chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) |
3 | Avillion (UK) Pfizer (USA - NY) | Cancer - Oncology - Rare diseases |
| 2014-08-11 | daratumumab in combination with lenalidomide and dexamethasone | front line multiple myeloma | 3 | Janssen Biotech - J&J (USA) Genmab (Denmark) | Cancer - Oncology - Rare diseases |
| 2014-08-08 | metadoxine extended release (MDX) | preclinical data | Alcobra (Israel) | CNS diseases - Mental diseases | |
| 2014-08-08 | Halaven® (eribulin mesylate) | advanced non-small cell lung cancer (NSCLC) that has progressed following two or more prior treatment regimens |
3 | Eisai (Japan) | Cancer - Oncology |
| 2014-08-07 | EDP-239 and DEB025 (alisporivir) | hepatitis C |
1 | Enanta Pharmaceuticals (USA - MA) Novartis (Switzerland) | Infectious diseases |
| 2014-08-07 | RNA splicing modifiers of the SMN2 gene | spinal muscular atrophy (SMA) |
preclinical | PTC Therapeutics (USA - NJ) | Neuromuscular diseases - Rare diseases - Genetic diseases |
| 2014-08-06 | Sym004 | non small cell lung cancer |
1b | Merck Serono, a Merck KGaA company (Germany) Symphogen (Denmark) | Cancer - Oncology |
| 2014-08-06 | Sym004 | metastatic colorectal cancer |
2b | Merck Serono, a Merck KGaA company (Germany) Symphogen (Denmark) | Cancer - Oncology |
| 2014-08-06 | mesenchymal precursor cells (MPCs) | congestive heart failure, advanced heart failure | 3 | Mesoblast (Australia) National Heart, Lung and Blood Institute, NIH (USA) | Cardiovascular diseases - Regenerative medicine |
| 2014-08-06 | MRX-6 | atopic dermatitis |
2 | Celsus Therapeutics (UK - USA) | Dermatological diseases - Immunological diseases - Inflammatory diseases |
| 2014-08-05 | NI-0101 | 1 | Novimmune (Switzerland) | Autoimmune diseases - Inflammatory diseases - Immunological diseases | |
| 2014-08-05 | Atu111 | sepsis | preclinical | Silence Therapeutics (UK) | Inflammatory diseases |
| 2014-08-05 | Fovista® | sub-retinal fibrosis in wet age-related macular degeneration (AMD) patients |
2 | Ophthotech (USA - NY) | Ophtalmological diseases |
| 2014-08-05 | SYN-004 | prevention of Clostridium difficile infections |
1 | Synthetic Biologics (USA - MD) | Infectious diseases |
| 2014-08-02 | combination of XALKORI® (crizotinib) and pembrolizumab | ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC) |
1b | Merck&Co (USA - NJ) Pfizer (USA - NY) | Cancer - Oncology |
| 2014-08-01 | ISIS-SMNRx | spinal muscular atrophy (SMA) | 3 | Isis Pharmaceuticals (USA - CA), now Ionis Pharmaceuticals (USA - CA) | Neuromuscular diseases - Rare diseases - Genetic diseases |
| 2014-07-31 | benralizumab | chronic obstructive pulmonary disease (COPD) | 3 | AstraZeneca (UK) | Allergic diseases – Inflammatory diseases – Respiratory diseases |
| 2014-07-31 | PD01A | Parkinson's disease |
1 | Affiris (Austria) | Neurodegenerative diseases - CNS diseases |
| 2014-07-30 | KAE609 (cipargamin) | malaria |
Novartis (Switzerland) | Infectious diseases - Parasitic diseases |
